The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study

Cancer Causes and Control

Volumn 27, Issue 4, 2016, Pages 569-581

  Naber, Steffie K ^a   de Kok, Inge M C M ^a   Matthijsse, Suzette M ^a   van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Computer simulation; Early detection of cancer; Human papillomavirus DNA tests; Papanicolaou test; Uterine cervical neoplasms

Indexed keywords

ADULT; AGE; ARTICLE; CANCER GRADING; CANCER RISK; CYTOLOGY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTERMETHOD COMPARISON; MICROSIMULATION; MORTALITY; OVER SCREENING; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIMULATION; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CANCER; WART VIRUS; CYTODIAGNOSIS; EARLY CANCER DIAGNOSIS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADULT; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84961201782     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-016-0732-7     Document Type: Article

References (59)

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19:1893–1907
2. Nanda K, McCrory DC, Myers ER et al (2000) Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132:810–819
3. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M (2006) Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 119:2372–2375
4. de Kok IM, van Rosmalen J, Rozemeijer K, Penning C, van Ballegooijen M (2014) How many cervical cancer cases can potentially be prevented using a more sensitive screening test at young age? Int J Cancer 134:460–466
5. Murphy PA, Schwarz EB, Dyer JM (2008) Cervical cancer screening practices of certified nurse-midwives in the United States. J Midwifery Womens Health 53:11–18
6. Franco EL, Rohan TE, Villa LL (1999) Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91:506–511
7. Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19
8. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J (2006) Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl 3):S3/78–S3/89
9. van Rosmalen J, de Kok IM, van Ballegooijen M (2012) Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG 119:699–709
10. de Kok IM, van Rosmalen J, Dillner J et al (2012) Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344:e670
11. Canfell K (2014) Progress in cancer screening: where are we in 2014? Cancer Forum 38:191–196
12. Moyer VA, U.S. Preventive Services Task Force (2012) Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156():880–891
13. Vink MA, Bogaards JA, Meijer CJ, Berkhof J (2014) Primary human papillomavirus DNA screening for cervical cancer prevention: can the screening interval be safely extended? Int J Cancer
14. Bell S, Porter M, Kitchener H, Fraser C, Fisher P, Mann E (1995) Psychological response to cervical screening. Prev Med 24:610–616
15. Mathias JS, Gossett D, Baker DW (2012) Use of electronic health record data to evaluate overuse of cervical cancer screening. J Am Med Inform Assoc 19:E96–E101
16. Cuzick J, Clavel C, Petry KU et al (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119:1095–1101
17. Saslow D, Solomon D, Lawson HW et al (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 137:516–542
18. von Karsa L, Arbyn M, De Vuyst H, et al. (2015) European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res (in press)
19. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V (2010) Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med 170:977–985
20. Berkowitz Z, Saraiya M, Sawaya GF (2013) Cervical cancer screening intervals, 2006 to 2009: moving beyond annual testing. JAMA Intern Med 173:922–924
21. Arbyn M, Rebolj M, De Kok IM et al (2009) The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 45:2671–2678
22. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ (1985) The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed 20:79–93
23. Statistics Netherlands (CBS) (2013) Statline database. Statistics Netherlands (CBS), The Hague
24. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ et al (2001) Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358:1782–1783
25. Anttila A, von Karsa L, Aasmaa A et al (2009) Cervical cancer screening policies and coverage in Europe. Eur J Cancer 45:2649–2658
26. Berkhof J, Coupe VM, Bogaards JA et al (2010) The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 127:2147–2158
27. Casparie M, Tiebosch AT, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24
28. Rijkaart DC, Berkhof J, Rozendaal L et al (2012) Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13:78–88
29. Bulkmans NW, Berkhof J, Bulk S et al (2007) High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 96:1419–1424
30. Rodriguez AC, Schiffman M, Herrero R et al (2008) Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100:513–517
31. Netherlands Cancer Registry (NCR) (2012) Age-specific and stage-specific cervical cancer incidence (2000–2010) and survival (1989–2009)
32. Goldie SJ, Kohli M, Grima D et al (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96:604–615
33. Mandelblatt JS, Lawrence WF, Womack SM et al (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287:2372–2381
34. van Ballegooijen M (1998) Effects and costs of cervical cancer screening. Erasmus University, Rotterdam, p 170
35. van den Hout WB, van der Linden YM, Steenland E et al (2003) Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95:222–229
36. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR (1997) Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 11:159–168
37. Habbema D, De Kok IM, Brown ML (2012) Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q 90:5–37
38. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202:1789–1799
39. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403
40. Insinga RP, Glass AG, Myers ER, Rush BB (2007) Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Mak 27:414–422
41. Korfage IJ, Essink-Bot ML, Westenberg SM, Helmerhorst T, Habbema JD, van Ballegooijen M (2014) How distressing is referral to colposcopy in cervical cancer screening?: a prospective quality of life study. Gynecol Oncol 132:142–148
42. Kitchener HC, Almonte M, Gilham C, et al. (2009) ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 13:1-150, iii-iv
43. Bulkmans NW, Rozendaal L, Snijders PJ et al (2004) POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 110:94–101
44. Ronco G, Giorgi-Rossi P, Carozzi F et al (2008) Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100:492–501
45. Naucler P, Ryd W, Tornberg S et al (2007) Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:1589–1597
46. Ronco G, Dillner J, Elfstrom KM, et al. (2013) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet
47. Chuck A (2010) Cost-effectiveness of 21 alternative cervical cancer screening strategies. Value Health 13:169–179
48. Cuzick J, Myers O, Hunt WC et al (2014) A population-based evaluation of cervical screening in the United States: 2008–2011. Cancer Epidemiol Biomark Prev 23:765–773
49. Rebolj M, van Ballegooijen M, Berkers LM, Habbema D (2007) Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 120:806–812
50. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ (2008) Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 100:308–320
51. De Vuyst H, Clifford G, Li N, Franceschi S (2009) HPV infection in Europe. Eur J Cancer 45:2632–2639
52. Dunne EF, Unger ER, Sternberg M et al (2007) Prevalence of HPV infection among females in the United States. JAMA 297:813–819
53. Saxena U, Sauvaget C, Sankaranarayanan R (2012) Evidence-based screening, early diagnosis and treatment strategy of cervical cancer for national policy in low-resource countries: example of India. Asian Pac J Cancer Prev 13:1699–1703
54. Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH (2012) Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. Cancer Prev Res (Phila) 5:11–17
55. Arbyn M, Kyrgiou M, Simoens C et al (2008) Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337:a1284
56. Jin G, LanLan Z, Li C, Dan Z (2014) Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch Gynecol Obstet 289:85–99
57. Committee on Practice Bulletins—Gynecology (2012) ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol 120:1222–1238
58. Kitchener HC, Gilham C, Sargent A et al (2011) A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 47:864–871
59. Elfstrom KM, Arnheim-Dahlstrom L, von Karsa L, Dillner J (2015) Cervical cancer screening in Europe: quality assurance and organisation of programmes. Eur J Cancer 51:950–968